Found: 15
Select item for more details and to access through your institution.
Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study.
- Published in:
- Acta Haematologica, 2008, v. 119, n. 2, p. 89, doi. 10.1159/000118628
- By:
- Publication type:
- Article
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq<sup>®</sup> (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.
- Published in:
- Haemophilia, 2018, v. 24, n. 4, p. 619, doi. 10.1111/hae.13493
- By:
- Publication type:
- Article
PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rh FVIII) in adults with severe haemophilia A.
- Published in:
- Haemophilia, 2017, v. 23, n. 5, p. 697, doi. 10.1111/hae.13251
- By:
- Publication type:
- Article
Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
- Published in:
- Haemophilia, 2017, v. 23, n. 2, p. 255, doi. 10.1111/hae.13167
- By:
- Publication type:
- Article
Prophylaxis vs. on-demand treatment with Nuwiq<sup>®</sup> (Human-cl rh FVIII) in adults with severe haemophilia A.
- Published in:
- Haemophilia, 2016, v. 22, n. 3, p. 374, doi. 10.1111/hae.12859
- By:
- Publication type:
- Article
Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq<sup>®</sup>) in adults with severe haemophilia A: efficacy and safety.
- Published in:
- Haemophilia, 2016, v. 22, n. 2, p. 225, doi. 10.1111/hae.12793
- By:
- Publication type:
- Article
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
- Published in:
- Haemophilia, 2015, v. 21, n. 6, p. 784, doi. 10.1111/hae.12721
- By:
- Publication type:
- Article
Efficacy and safety of a recombinant factor IX (Bax326)<sup>a</sup> in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
- Published in:
- Haemophilia, 2014, v. 20, n. 5, p. 651, doi. 10.1111/hae.12419
- By:
- Publication type:
- Article
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
- Published in:
- Haemophilia, 2014, v. 20, n. 1, p. 15, doi. 10.1111/hae.12228
- By:
- Publication type:
- Article
Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine<sup>®</sup>) and a recombinant factor IX (BeneFIX<sup>®</sup>) in patients with severe haemophilia B.
- Published in:
- Haemophilia, 2013, v. 19, n. 5, p. 674, doi. 10.1111/hae.12148
- By:
- Publication type:
- Article
A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine.
- Published in:
- Haemophilia, 2011, v. 17, n. 4, p. 590, doi. 10.1111/j.1365-2516.2010.02470.x
- By:
- Publication type:
- Article
An open clinical study assessing the efficacy and safety of Factor IX Grifols<sup>®</sup>, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
- Published in:
- Haemophilia, 2010, v. 16, n. 2, p. 240, doi. 10.1111/j.1365-2516.2009.02090.x
- By:
- Publication type:
- Article
Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols<sup>®</sup>) with a 6-month follow up in previously treated patients with severe haemophilia B.
- Published in:
- Haemophilia, 2009, v. 15, n. 6, p. 1243, doi. 10.1111/j.1365-2516.2009.02052.x
- By:
- Publication type:
- Article
Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A.
- Published in:
- Haemophilia, 2007, v. 13, n. 1, p. 9, doi. 10.1111/j.1365-2516.2006.01412.x
- By:
- Publication type:
- Article
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2006, v. 132, n. 2, p. 99, doi. 10.1007/s00432-005-0050-z
- By:
- Publication type:
- Article